Financial Survey: Better Therapeutics (BTTX) & The Competition

Better Therapeutics (NASDAQ:BTTXGet Rating) is one of 33 publicly-traded companies in the “Health services” industry, but how does it compare to its competitors? We will compare Better Therapeutics to similar businesses based on the strength of its valuation, dividends, risk, analyst recommendations, earnings, profitability and institutional ownership.

Insider & Institutional Ownership

7.5% of Better Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of shares of all “Health services” companies are owned by institutional investors. 59.4% of Better Therapeutics shares are owned by company insiders. Comparatively, 21.6% of shares of all “Health services” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Better Therapeutics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Better Therapeutics 0 0 2 0 3.00
Better Therapeutics Competitors 7 130 274 0 2.65

Better Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 865.52%. As a group, “Health services” companies have a potential upside of 112.07%. Given Better Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Better Therapeutics is more favorable than its competitors.

Earnings and Valuation

This table compares Better Therapeutics and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Better Therapeutics $10,000.00 -$40.33 million -0.72
Better Therapeutics Competitors $1.36 billion -$98.47 million 29.16

Better Therapeutics’ competitors have higher revenue, but lower earnings than Better Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Better Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Better Therapeutics N/A -200.73% -114.68%
Better Therapeutics Competitors -325.87% -481.74% -38.64%

Volatility & Risk

Better Therapeutics has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, Better Therapeutics’ competitors have a beta of 1.48, indicating that their average stock price is 48% more volatile than the S&P 500.

Summary

Better Therapeutics beats its competitors on 7 of the 12 factors compared.

About Better Therapeutics

(Get Rating)

Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.

Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.